Item 6 of the Schedule 13D is amended and supplemented as follows: On December 18, 2025, the Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund") and Perceptive Xontogeny Venture Fund II, LP ("PXV II") entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with the Issuer, pursuant to which the Master Fund and PXV II will acquire an aggregate of 1,319,026 shares of Common Stock at a price of $6.35 per share, pre-funded warrants to purchase 1,830,580 shares of Common Stock at a price of $6.34 per share and with an exercise price of $0.001 per share (the "Pre-Funded Warrants"), warrants to purchase 5,118,109 shares of Common Stock with an exercise price of $6.35 per share (the "Series A Warrants"), and warrants to purchase 4,724,408 shares of Common Stock with an exercise price of $7.62 per share (the "Series B Warrants," and together with the Pre-Funded Warrants and the Series A Warrants, the "Warrants") (the "Private Placement"). The Private Placement is expected to close on December 23, 2025 (the "Closing"), subject to the satisfaction of customary closing conditions. The Series A Warrants will be exercisable after the earlier of (1) the latest of (a) June 30, 2026, (b) the date on which the Issuer announces the enrollment of the 500th subject or the last subject, whichever is earlier, in its ELAINE-3 trial, and (c) the date on which the U.S. Food and Drug Administration approves or issues a complete response letter to Eli Lilly & Co.'s marketing application for imlunestrant in combination with abemaciclib in breast cancer, and (2) October 31, 2026. The Series B Warrants will be exercisable after the later of (1) June 30, 2026 and (2) the date of the completion of the public readout of topline results of the Issuer's ELAINE-3 trial. The terms of the Warrants will provide that the Warrants may not be exercised if, after such exercise, the Reporting Persons, together with their Attribution Parties (as defined in the Warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 19.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Beneficial Ownership Limitation"). The foregoing description of the Securities Purchase Agreement, the Pre-Funded Warrants, the Series A Warrants, and the Series B Warrants is qualified in its entirety by reference to the full text of the agreements, copies of which are included as Exhibit 1, Exhibit 2, Exhibit 3, and Exhibit 4 hereto, respectively. Also on December 18, 2025, the Issuer entered into an agreement with Sermonix Pharmaceuticals, Inc. ("Sermonix") pursuant to which Sermonix granted to the Issuer the exclusive license and right to develop, manufacture and commercialize oral forms of the selective estrogen-receptor modulator known as lasofoxifene in certain territories. In exchange for the granting of such license, the Issuer will issue to Sermonix pre-funded warrants to purchase an aggregate of 5,502,402 shares of Common Stock with an exercise price of $0.001 per share (the "Sermonix Pre-Funded Warrants") pursuant to a Securities Purchase Agreement dated December 18, 2025 (the "Sermonix Securities Purchase Agreement"). An affiliate of the Reporting Persons currently holds approximately 29% of the outstanding capital stock of Sermonix (excluding securities convertible into shares of Sermonix capital stock). The terms of the Sermonix Pre-Funded Warrants will provide that the Sermonix Pre-Funded Warrants may not be exercised if, after such exercise, Sermonix, together with its Attribution Parties (as defined in the Sermonix Pre-Funded Warrants) would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 4.99% of the shares of Common Stock then issued and outstanding after giving effect to such exercise (the "Sermonix Beneficial Ownership Limitation"). The Sermonix Beneficial Ownership Limitation may be increased or decreased by Sermonix with 61 days' written notice to the Company; provided, however, that such percentage may in no event exceed 19.99% prior to receipt of the Sermonix Stockholder Approval (as defined in the Sermonix Securities Purchase Agreement). The foregoing description of the Sermonix Securities Purchase Agreement and the Sermonix Pre-Funded Warrants is qualified in its entirety by reference to the full text of the agreements, copies of which are included as Exhibit 5 and Exhibit 6 hereto, respectively.

Item 7 of the Schedule 13D is amended and supplemented as follows: Exhibit 1 Securities Purchase Agreement dated December 18, 2025, by and among the Issuer, the Master Fund, PXV II, and the other parties thereto (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K/A filed with the Securities and Exchange Commission on December 18, 2025) Exhibit 2 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Issuer's Current Report on Form 8-K/A filed with the Securities and Exchange Commission on December 18, 2025) Exhibit 3 Form of Series A Warrant (incorporated by reference to Exhibit 4.2 to the Issuer's Current Report on Form 8-K/A filed with the Securities and Exchange Commission on December 18, 2025) Exhibit 4 Form of Series B Warrant (incorporated by reference to Exhibit 4.3 to the Issuer's Current Report on Form 8-K/A filed with the Securities and Exchange Commission on December 18, 2025) Exhibit 5 Securities Purchase Agreement dated December 18, 2025, by and among the Issuer and Sermonix (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K/A filed with the Securities and Exchange Commission on December 18, 2025) Exhibit 6 Form of Sermonix Pre-Funded Warrant (incorporated by reference to Exhibit 4.4 to the Issuer's Current Report on Form 8-K/A filed with the Securities and Exchange Commission on December 18, 2025)